Seeking Alpha

Teva Pharmaceutical Industries Ltd. (TEVA)

()

Analysis
Articles1 new
Instablogs
StockTalks1 new
Sentiment
Comments4 new

News & PR
Market Currents

Buzz
Twitter: TEVA

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

14 Non-U.S. Companies from the Nasdaq 100 Index

Dec 1 • David Hunkar • 1 Comment
Why Should You Own Dividend-Paying Stocks?

Nov 30 • David Hunkar • 5 Comments
9 Stocks in Focus at Better Investing

Nov 29 • David I. Templeton • 4 Comments
8 HealthCare Stocks with 3%+ Dividends

Nov 29 • Hao Jin • 9 Comments
Israel's Current Economic Miracle: Lessons for the U.S. Economy?

Nov 28 • Joseph L. Shaefer • 14 Comments
Why a Market Crash Doesn’t Matter

Nov 22 • Chuck Carnevale • 86 Comments
Is Tech Overvalued?

Nov 22 • Hao Jin • 4 Comments
Santarus, Depomed Poised to Gain from Anticipated Sales of Glumetza

Nov 16 • R. Saito • 2 Comments
Are Markets Headed for an 800-Point Blow-Off Day?

Nov 12 • Joseph L. Shaefer • 26 Comments
Bionovo: Challenges Ahead, But Poised to Move Higher

Nov 9 • ThreeBrothersHealth.com • 1 Comment
Cephalon's Upside and Downside

Nov 8 • Steve Alexander • 1 Comment
A 130 / 30 Global Pharma Strategy

Nov 5 • Mike Havrilla • 2 Comments
Teva Reports Strong Third Quarter

Nov 4 • Zacks.com • 1 Comment
My Two Healthcare Favorites

Nov 3 • J. Royden Ward • 3 Comments
Wall Street Breakfast: Must-Know News

Nov 3 • SA Editor Eli Hoffmann • 17 Comments
Four ETFs with Great Apple Exposure

Oct 20 • ETF Daily News • 1 Comment
Biotech: Q3 Market Update

Oct 16 • R. Scott Raynovich • Comment!
Shumway: Another Hedge Fund Falls for BofA

Sep 30 • Market Folly • Comment!
Israel ETFs Might Be the ‘Ideal Overlooked Destination’

Sep 29 • Tom Lydon • 1 Comment
BioMed News Bytes: Arena, Momenta, Vivus

Sep 20 • Mike Havrilla • Comment!
Teva’s Copaxone Challenged by Mylan

Sep 18 • Zacks.com • Comment!
Smile Communications: Eye on the 'Other' Israel

Sep 8 • Ron Sommer • Comment!
Novartis: Powering into the Multiple Sclerosis Market

Sep 8 • Richard Sater • 3 Comments
Clolar Decision Aside, Genzyme's Still a Near-Term Sell

Sep 2 • Mark Mitchell • Comment!
5 Anomalies in the Current U.S. Markets

Aug 31 • Dr. Stephen Leeb • 13 Comments
Mylan: Generic Drugmaker with a Strong Portfolio

Aug 28 • BioPharma Investor • 8 Comments
Protalix Biotherapeutics: FDA Fast Track for Gaucher Treatment

Aug 26 • BioPharma Investor • 4 Comments
Weekly Street Sentiment: Sell-Side Somewhat Disinterested

Aug 25 • First Coverage • 1 Comment
The Annihilation of American Automakers: How to Take Advantage of This Trend

Aug 24 • Sara Nunnally • 2 Comments
Merck Wins Legal Battle Against Teva

Aug 20 • Zacks.com • 1 Comment
Teva Pharmaceutical: Predictable Growth, Good Value

Aug 20 • Chuck Carnevale • 9 Comments
Market Sentiment: Sell-Side Awaits Catalyst

Aug 11 • First Coverage • Comment!
Spotlight on Biotech: 10 Promising Companies

Aug 9 • Ron Sommer • 2 Comments
Goldilocks of Goldman, Market Bears and Positions for This Market

Aug 7 • Global Investing Editor • 7 Comments
Using Put Options to Purchase Big Techs for Less

Aug 6 • Marco Hickey • Comment!
Caraco Pharmaceutical: Underappreciated and Undervalued, Part 2

Aug 4 • Pakiya • 8 Comments
Caraco Pharmaceutical: Underappreciated and Undervalued, Part 1

Aug 4 • Pakiya • Comment!
FPL Group and TEVA Remain Strong Growth Stocks

Jul 29 • Dr. Stephen Leeb • 5 Comments
Teva Reports Mixed Results

Jul 28 • Zacks.com • 2 Comments
Wall Street Breakfast: Must-Know News

Jul 28 • SA Editor Rachael Granby • 15 Comments
20 Option Ideas for This Market

Jul 28 • Marco Hickey • Comment!

Teva Pharmaceutical Industries Ltd. (TEVA)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers